European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-09-01 to 2023-09-01.)
ArticleCitations
Epidemiology of heart failure718
Myocardial localization of coronavirus in COVID‐19 cardiogenic shock691
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure516
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci428
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O275
Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis235
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)211
Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology189
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th180
COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease174
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rational173
Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology172
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardio159
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications154
Changes in m6A RNA methylation contribute to heart failure progression by modulating translation154
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial152
The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic143
Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015141
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and141
Phenomapping of patients with heart failure with preserved ejection fraction using machine learning‐based unsupervised cluster analysis133
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology131
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology128
Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years123
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial 118
Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure118
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F116
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure116
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis116
Lung ultrasound‐guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS‐HF study)111
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust109
Improving risk prediction in heart failure using machine learning108
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 201997
Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study96
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology94
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity93
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients91
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association 91
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study89
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care87
Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies86
Validation of the HFA‐PEFF score for the diagnosis of heart failure with preserved ejection fraction84
Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction83
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatme81
Endothelium‐dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction81
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study80
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London78
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial76
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF76
Depression and heart failure: the lonely comorbidity75
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy74
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper73
Hypertrophic cardiomyopathy: the future of treatment72
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction72
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan70
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long69
An expert consensus document on the management of cardiovascular manifestations of Fabry disease69
Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome68
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection67
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) 66
Selenium and outcome in heart failure66
Bone marrow‐derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4‐year follow‐up of the MSC‐HF trial65
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization65
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study64
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure64
Telemonitoring versus standard care in heart failure: a randomised multicentre trial64
0.02544903755188